Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population
Open Access
- 23 April 2024
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (6) , 1526-1534
Abstract
ObjectiveOur objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease-modifying therapy within this prevalent cohort.MethodsThis is a retrospective, observational study of patients that had contact with the University of Colorado Health System from 2012 to 2020. We queried Health Data Compass, a data warehouse, for patient data and applied the MS Prevalence Workgroup Algorithm to generate a prevalent cohort. We calculated prevalence as of 31 December 2020, and stratified by age, sex, race, and ethnicity. Payer information and treatment exposure were obtained from linked claims from the Colorado All Payers Claim Database. Disease-modifying therapies were classified as highly effective and moderately effective based on the clinical trial, TREAT-MS (NCT03500328).ResultsFrom a population of 1,382,821 individuals, 8557 people with MS were captured. Age-adjusted prevalence of MS as of 31 December 2020 was 572.3 per 100,000 with a mean age of 47.36. Prevalence varied between demographic subgroups, with the lowest prevalence in Hispanic men (215.6) and highest in White (824.1) and Black women (820.1). Overall disease-modifying therapy exposure was 62.4%, with increased highly effective therapy use and a corresponding decrease in moderately effective therapy use on a yearly basis.InterpretationMS is highly prevalent in a representative Colorado cohort. Overall treatment and proportion of highly effective therapy exposure increased significantly during a critical period of MS therapeutic advances, indicating a shift in disease management driven sharply by the availability of on-label anti-CD20 therapy.Keywords
Funding Information
- National Multiple Sclerosis Society (PP‐1909‐35061)
This publication has 19 references indexed in Scilit:
- Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020JAMA Neurology, 2023
- Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic RegionJAMA Neurology, 2023
- Cautions When Using Race and Ethnicity in Administrative Claims Data SetsJAMA Health Forum, 2022
- Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019Neurology and Therapy, 2022
- Prevalence of multiple sclerosis and treatment utilization in a large, highly diverse populationMultiple Sclerosis and Related Disorders, 2022
- Migrating a research data warehouse to a public cloud: challenges and opportunitiesJournal of the American Medical Informatics Association, 2021
- Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United StatesMultiple Sclerosis Journal, 2019
- Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic ReviewNeuroepidemiology, 2013
- The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and serviceBrain, 2012
- Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2011